PharmaShots Interview: Janssen’s Kiran Patel Shares Insights on Amivantamab for Metastatic EGFR Exon 20+ NSCLC

In a recent interview with PharmaShots, Kiran Patel, Vice President Clinical Development, Solid Tumor Franchise at Janssen shared his views on the regulatory submission of Amivantamab for the Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations. Shots: Janssen reported the BLA submission to the US FDA seeking approval of Amivantamab for the…

BySenior EditorJanuary 13, 2021

EVENTS

Exclusive Webinar: Health Economics & Outcomes Research /Health Technology Assessment: The evolving role in the Indian Healthcare Ecosystem

Shots: Intellimed in collaboration with alpha MD & IMPA along with PharmaShots as the media partner is gladly organizing a webinar on 'Health Economics & Outcomes Research /Health Technology Assessment: The evolving role in the Indian Healthcare Ecosystem' The objective of the webinar is to discuss the need for affordable healthcare in India and the…

BySenior EditorJanuary 13, 2021

Announcements

PharmaShots Wishes you a Merry Christmas and a Happy New Year

Shots: Thank you for your overwhelming affection and support throughout the year. This year we achieved a massive increase in subscribers PharmaShots mobile app is ready and we planned to launch our PharmaShots mobile app in January 2021 May this holiday season fills your life with happiness and wealth. Wish you a Merry Christmas and…

BySenior EditorDecember 24, 2020

VIEWPOINTS

PharmaShots Interview: FibroGen’s Peony Yu Shares Insight on Roxadustat

In a recent interview with PharmaShots, Peony Yu, Chief Medical Officer of FibroGen shared her insights and highlights on data of Roxadustat Shots: FibroGen presented new efficacy and safety analyses from the roxadustat global P-III program at ASN Kidney Week 2020 Reimagined. FibroGen and its partners, AstraZeneca and Astellas, presented 42 abstracts, including 2 late-breaker poster presentations,…

BySenior EditorDecember 7, 2020

TOP 20

Top 20 Immunology Companies Based 2019 Immunology Segment Revenue

Immunology is an important branch of science which deals with the study of the immune system. The immune system is a highly regulated and balanced system and when the balance is disturbed- the disease can result. A lot of this work has importance in the development of new therapies and treatments that can handle or…

ByPrince GiriOctober 22, 2020

VIEWPOINTS

PharmaShots Interview: QIAGEN’s Kai te Kaat Shares Insights on QIAprep& Viral RNA UM Kit

In a recent interview with PharmaShots, Kai te Kaat, the Vice President, Head of Franchise Oncology, MDx at QIAGEN shares his insights and highlights on QIAprep& Viral RNA UM Kit. Shots: QIAGEN to launch the QIAprep& Viral RNA UM Kit, designed to simplify and accelerate PCR swab analysis and remove key testing bottlenecks for Covid-19 and other RNA viruses The…

BySenior EditorOctober 19, 2020

THOUGHTSPOT

COVID-19 Vaccine Distribution the Next Supply Chain Frontier

An overview of various aspects of the supply chain that would be crucial in the production and distribution of COVID-19 Vaccine. Write to us at connect@pharmashots.com if you want a PDF copy of this report. Over the past seven months, the global pandemic caused by the spread of SARS-CoV-2, the virus that leads to coronavirus disease (COVID-19),…

BySenior EditorAugust 13, 2020

Announcements

PharmaShots Celebrates Successful Accomplishment of Two Years

Shots: PharmaShots started its journey in July 2018 as a concise news delivery service and is proud to announce the completion of two years, with many more to come. Till now, PharmaShots has published 3,057 posts delivered to our 3000+ subscribers On the 2nd anniversary, PharmaShots announced 'PharmaShots Bespoke' its new tailor-made, and targeted news…

BySenior EditorJuly 25, 2020

INSIGHTS+

PharmaShots’ Key Highlights of First Quarter 2020

The first quarter of 2020 includes big news regarding global companies. The highlight of the quarter is the acquisition of QIAGEN by ThermoFisher for ~$11.5B, Danaher's acquisition of the biopharma business of GE Life Sciences in an all-cash transaction for ~$21.4B. Numerous alliances are there which include Fosun's agreement with BioNTech to develop and commercialize…

BySenior EditorApril 8, 2020

INSIGHTS+

Insights+: The US FDA New Drug Approvals in February 2020

The US FDA has approved multiple NDAs and BLAs in Feb 2020, leading to treatments for patients and advances in health care The Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have approved 13 novel products so far in 2020, including 10 in Feb and 3 in Jan…

BySenior EditorMarch 27, 2020

PharmaShots Interview: Janssen’s Kiran Patel Shares Insights on Amivantamab for Metastatic EGFR Exon 20+ NSCLC

Exclusive Webinar: Health Economics & Outcomes Research /Health Technology Assessment: The evolving role in the Indian Healthcare Ecosystem

PharmaShots Wishes you a Merry Christmas and a Happy New Year

PharmaShots Interview: FibroGen’s Peony Yu Shares Insight on Roxadustat

Top 20 Immunology Companies Based 2019 Immunology Segment Revenue

PharmaShots Interview: QIAGEN’s Kai te Kaat Shares Insights on QIAprep& Viral RNA UM Kit

COVID-19 Vaccine Distribution the Next Supply Chain Frontier

PharmaShots Celebrates Successful Accomplishment of Two Years

PharmaShots’ Key Highlights of First Quarter 2020

Insights+: The US FDA New Drug Approvals in February 2020

Contact US

FOLLOW US